No Data
No Data
Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4%
Chimeric Therapeutics (ASX:CHM) said the Phase 1/2 multi-center and first-in-human clinical trial for its CHM CDH17 CAR T cell therapy is now open for enrollment at SCRI Oncology Partners in Nashville
Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial
Chimeric Therapeutics (ASX:CHM) secured ethics approval for the start of the multi-site Phase 1/2 clinical trial of CHM CDH17 cell therapy in patients with advanced gastrointestinal cancers, according
Chimeric Therapeutics Reopens Enrollment in Phase 1B Cell Therapy Study
Chimeric Therapeutics (ASX:CHM) said that enrollment in the Phase 1B study of CHM CORE-NK cell therapy plus vactosertib has reopened, according to a Thursday filing with the Australian Securities Exch
Chimeric Therapeutics Appoints COO; Shares Rise 4%
Chimeric Therapeutics (ASX:CHM) appointed Rebecca McQualter as its chief operating officer, the clinical stage cell therapy company said Thursday. McQualter has previously worked at companies such as
Chimeric Therapeutics' CEO/Managing Director Steps Down; Shares Plunge 20%
Chimeric Therapeutics (ASX:CHM) said Jennifer Chow has given notice of her resignation as the company's chief executive officer and managing director, effective May 24, according to a Wednesday filing
Chimeric Therapeutics Obtains Patent Application Covering CORE-NK Technology; Shares Up 3%
Chimeric Therapeutics (ASX:CHM) said that the US Patent & Trademark Office has allowed for issuance of a patent application covering the CORE-NK platform technology for blood cancers and solid tumors,
No Data